Articles From: Given Imaging Receives Clearance for the Third Generation PillCam(R) SB System in Japan to Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival


YOQNEAM, Israel, Sept.
Sign-up for Given Imaging Receives Clearance for the Third Generation PillCam(R) SB System in Japan investment picks
2013/9/23
Biogen Idec (NASDAQ: BIIB) will present 58 data sets from the company’s multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5.
Sign-up for Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS investment picks
New MasterCard Study Puts Canada among Most Advanced in the World for Cashless Payments Canada NewsWire Canada Identified as Nearly Cashless, along with Belgium and France To tweet this news, copy and paste http://bit.ly/18IuRlj to your Twitter handle with the hashtag #MasterCard and #cashless TORONTO , Sept.
Sign-up for New MasterCard Study Puts Canada among Most Advanced in the World for Cashless Payments investment picks
Los Angeles, California, Sept.
Sign-up for Embarr Downs Announces Corporate Update investment picks
By Craig Stephen HONG KONG (MarketWatch) -- The proposed Shanghai free-trade zone (FTZ) to be launched in a matter of days continues to stir controversy in Hong Kong.
Sign-up for Will Shanghai be free to trade? investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0899908001&sourceType=1 CARSON CITY, NEVADA --
Sign-up for Siga Resources Provides Corporate Update investment picks
2013/9/22
SHANGHAI , Sept.
Sign-up for Huntsman Opens New Asia Pacific Technology Center in Shanghai investment picks
RIDGEFIELD, Conn.
Sign-up for Northern Tier Energy Reports Operational Issue with Crude Unit investment picks
2013/9/22
--Only Rentrak Provides the Global Standard in Box Office Reporting--
Sign-up for Rentrak Announces Worldwide Box Office Results For Weekend Of September 22, 2013 investment picks
2013/9/22
By Isabella Steger and Te-Ping Chen HONG KONG--Typhoon Usagi made landfall in China's southern Guangdong province on Sunday night, killing two people and bringing heavy rain to the region.
Sign-up for Typhoon Usagi slams into mainland China investment picks
http://media.marketwire.com/attachments/200906/438886_oracleresized.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1053060&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Oracle OpenWorld Kicks Off a Full Week of Education, Insight and Opportunities for Customers From Around the Globe investment picks
2013/9/22
CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data investment picks
World's Largest Annual Gathering of the Radiation Oncology Community Provides Multiple Opportunities to Learn about the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems SUNNYVALE, Calif.
Sign-up for Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013 investment picks
2013/9/22
By Myra P.
Sign-up for BlackBerry, Apple, Red Hat are stocks to watch investment picks
Company strengthens OTN Solutions Portfolio to address the growing gap between current ASSP and ASIC industry offerings LONDON , Sept.
Sign-up for New Xilinx OTN SmartCORE IP for High Capacity Combined Ethernet and 100G OTN Switching Platforms and Packet-Optical Transport Systems investment picks
SOUTH SAN FRANCISCO, Calif., Sept.
Sign-up for Five Prime Therapeutics Announces Pricing of Initial Public Offering investment picks
2013/9/25
NEW YORK (MarketWatch) -- J.C. Penney Co.
Sign-up for J.C. Penney Co. slumps to a near 13-year low investment picks
THCFinder.com joins the M3Hub™ CAVE CREEK, Ariz.
Sign-up for Endexx enters definitive agreement to acquire THCFinder.com investment picks
The Chief Executive of Metro AG (MEO.XE) indicated that the German retailer may reach its guidance for the January-to-September period, according to pre-released quotes from an interview to be published Monday in WirtschaftsWoche.
Sign-up for Metro AG CEO Feels Comfortable With Guidance, Aims for Kaufhof Sale -- Report investment picks
The Chief Financial Officer of Luxembourg's RTL Group (RTL.BT), Elmar Heggen, confirmed the television broadcaster's full-year guidance, according to pre-released excerpts of an interview to be published Sunday in Frankfurter Allgemeine Sonntagszeitung.
Sign-up for RTL Confirms Guidance, Says All Foreign Stations Profitable -- Report investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating if a securities violation was committed by J.C. Penney Company, Inc., (NYSE: JCP) when it made specific representations about the company’s liquidity and the need to raise cash.
Sign-up for Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of J.C. Penney Company investment picks
2013/9/28
In recognition of World Rabies Day, and in an effort to reduce the number of people dying of the disease, Merck Animal Health (known as MSD Animal Health outside the USA and Canada) is proud to support canine rabies vaccination programs in some of the most at-risk regions in the world.
Sign-up for Merck Animal Health Proudly Supports Vaccination Programs Targeted at Reducing Disease in Domestic Pets investment picks
Synta Pharmaceuticals Corp.
Sign-up for Synta Announces Presentation of Ganetespib Results at the 2013 European Cancer Congress investment picks
2013/9/28
By AnnaMaria Andriotis The likelihood that a mortgage application will be approved varies widely by bank.
Sign-up for UPDATE: The bank that rejects the most mortgages investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced the results from Roche’s TH3RESA Phase III trial being presented today at the European Cancer Congress (ECC) in Amsterdam (abstract #LBA15). The findings were accepted as late-breaking data and also included in the Congress’s official press program.
Sign-up for ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced updated results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAF V600 mutation.
Sign-up for Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013 investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113 , in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
Sign-up for ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer investment picks
Trial Evaluated Nearly 1,000 Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif.
Sign-up for Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Given Imaging Receives Clearance for the Third Generation PillCam(R) SB System in Japan to Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity